Abstract
The tolerability and efficacy of a long-acting im applicable form of bromocriptine (Parlodel LAR®) was tested in a double-blind approach in 20 patients with hyperprolactinemia or prolactinoma, 17 of them complaining of persistent side effects on oral treatment with dopamine agonists. The study-code revealed similar characteristics for age, sex, weight, clinical symptoms and previous therapy in both groups but prolactin serum levels were higher in the verum group even though the difference was not significant. In all 10 patients receiving Parlodel LAR® prolactin serum concentrations were significantly suppressed and tumor size was reduced in 5 of the 9 patients with visible tumors when controlled after 28 days. In contrast, no significant change in serum prolactin levels was observed in the placebo group and tumor size of all visible tumors was not altered. Side effects typically reported for dopamine agonists started 3 h after application in the verum group and were significantly different to the unspecific side effects reported in the placebo group during the first 72 h. Thereafter systemic tolerability was indistinguishable between both groups. The local tolerability at the injection site was excellent for both, Parlodel LAR® and placebo.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Johnston D.G., Prescott R.W.G., Kendall-Taylor P., Hall K., Crombie A.L., Hall R., McGregor A., Watson M.J., Cook D.B. Hyperprolactinemia, long-term effects of bromocriptine. Am. J. Med. 75: 868, 1983.
Del Pozo E., Gerber L., Hunziker S. Response to bromocriptine therapy in 115 prolactinoma cases. In: Stefanis C., Tolis G. (Eds.) Prolactin and prolactinomas. Raven Press, New York, 1983, p. 403.
Robinson A.G., Nelson P.B. Prolactinomas in women: current therapy. Ann. Intern. Med. 99: 115, 1983.
Wass J.A.H., Besser G.M. The medical management of hormone-secreting tumors of the pituitary. Annu. Rev. Med. 34: 283, 1983.
Molitch M.E., Elton R.L., Blackwell R.E., Caldwell B., Chang R.J., Jaffe R., Joplin G., Robbins R.J., Tyson J., Thorner M.O. Bromocriptine as primary therapy for macroadenomas: results of a prospective multicenter study. J. Clin. Endocrinol. Metab. 60: 698, 1985.
Spark R.F., Baker R., Bienfang D.C., Bergland R. Bromocriptine reduces pituitary tumor size and hypersecretion. JAMA 247: 311, 1982.
Barbieri R.L., Ryan K.J. Bromocriptine: endocrine pharmacology and therapeutic applications. Fertil. Steril. 39: 727, 1983.
Faglia G., Conti A., Muratori M., Togni E., Travaglini P., Zanotti A., Mailland F. Dihydroergocriptine in management of microprolactinomas. J. Clin. Endocrinol. Metab. 65: 779, 1987.
Van’t Verlaat J.W., Lancranjan I., Hendriks M.J., Crough R.J.M. Primary treatment of macroprolactinomas with Parlodel LAR. Acta Endocrinol. (Copenh.). 119: 51, 1988.
Lancranjan I., Cavagnini F., Felley C., Pagani M.D., Montini M., Felber J.P. Long-term treatment of prolactinomas with a long-acting injectable form of bromocriptine. In: Genazzani A.R., Montemagno U., Nappi C., Petraglia F. (Eds.), The brain and female reproductive function. Parthenon Publishing, Carnforth, 1987, p. 569.
Ciccarelli E., Camanni F., Miola C., Besser G.M., Avataneo T., Grossman A. Long-term treatment with a new repeatable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia. Fertil. Steril. 52: 930, 1989.
Schettini G., Lombardi G., Merola B., Colao A., Miletto P., Caruso E., Lancranjan I. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of a long-acting repeatable form of bromocriptine (Parlodel LAR). Clin. Endocrinol. (Oxf.) 33: 161, 1990.
Thorner M.O., Burdman J.A., Calabrese M.T., Valdenegro C.A., Vance M.L., MacLeod R.M. Dopamine agonists and prolactinomas: clinical and basic considerations of the mechanisms of action. In: Calne D.B., McDonald R.J., Horowski R., Wuttke W. (Eds.), Lisuride and other dopamine agonists. Raven Press, New York, 1983, p. 213.
Thorner M.O., Schran H.F., Evans W.F., Rogol A.D., Morris J.L., MacLeod R.M. A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: a study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine. J. Clin. Endocrinol. Metab. 50: 1026, 1980.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schulz, A., Lancranjan, I., Schürmeyer, T. et al. Efficacy and tolerability of a long-acting intramuscularly injectable depot preparation of bromocriptine: the results of a double blind study. J Endocrinol Invest 14, 469–474 (1991). https://doi.org/10.1007/BF03346845
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03346845